Document Detail


Effective treatment of female androgenic alopecia with dutasteride.
MedLine Citation:
PMID:  16167423     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Dihydrotestosterone is the main molecule responsible for androgenic alopecia. Finasteride, which reduces transformation of testosterone into dihydrotestosterone and decreases dihydrotestosterone activity, is approved for treatment of androgenic alopecia in men. We describe the case of a 46-year-old woman with androgenic alopecia, non-responsive to minoxidil, who initially benefited from finasteride. Due to only limited improvement after finasteride and persisting profound psychological distress resulting from androgenic alopecia, another 5-reductase inhibitor, dutasteride, was introduced. Clinical evaluation and trichogram were applied for assessment of dutasteride efficacy in this patient. Additionally, mean hair diameter was monitored by means of computer dermoscopy. After 6 months of therapy, significant improvement was observed and after 9 months the clinical diagnosis of androgenic alopecia could no longer be made in this patient. No side effects were observed. In conclusion, theoretical data and our experience in this case show that dutasteride might develop into a true alternative in treatment of androgenic alopecia.
Authors:
Malgorzata Olszewska; Lidia Rudnicka
Related Documents :
12656943 - Ziprasidone-associated mania: a case series and review of the mechanism.
2128853 - Adverse events reported in association with the use of monoclonal antibody purified fac...
20129513 - Anatomical landmark asymmetry assessment in the lumbar spine and pelvis: a review of re...
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Journal of drugs in dermatology : JDD     Volume:  4     ISSN:  1545-9616     ISO Abbreviation:  J Drugs Dermatol     Publication Date:    2005 Sep-Oct
Date Detail:
Created Date:  2005-09-19     Completed Date:  2005-10-26     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101160020     Medline TA:  J Drugs Dermatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  637-40     Citation Subset:  IM    
Affiliation:
Department of Dermatology, Warsaw Medical School, Warsaw, Poland. malgorzataolszewska@yahoo.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Alopecia / drug therapy*,  pathology
Azasteroids / adverse effects,  therapeutic use*
Enzyme Inhibitors / adverse effects,  therapeutic use*
Female
Finasteride / therapeutic use
Humans
Middle Aged
Minoxidil / therapeutic use
Scalp / pathology
Skin / pathology
Testosterone 5-alpha-Reductase / antagonists & inhibitors*
Chemical
Reg. No./Substance:
0/Azasteroids; 0/Enzyme Inhibitors; 0/dutasteride; 38304-91-5/Minoxidil; 98319-26-7/Finasteride; EC 1.3.99.5/Testosterone 5-alpha-Reductase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Punctate palmoplantar keratoderma (Buschke-Fischer-Brauer disease) with psoriasis: a rare associatio...
Next Document:  Cutaneous leiomyomatosis and parotid pleomorphic adenoma.